We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AB2 Bio

News List

AB2 Bio and WuXi Biologics Enter Collaboration contractpharma
October 30, 2020
Set-up and accelerate commercial-scale manufacturing of Tadekinig alfa.
WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa PharmaSources.com
October 30, 2020
WuXi Biologics and AB2 Bio Ltd., announced that they have entered into a collaboration to set-up and accelerate commercial-scale manufacturing of Tadekinig alfa.
AB2 Bio Announces Readiness for Recruitment in Pivotal Phase 3 Trial of Tadekinig Alfa, a Novel Human Recombinant Interleukin-18 Binding Protein, in Children with Genetic Diagnosis of NLRC4-MAS Mutation or XIAP Deficiency, with Amended Design in the U.S. b3cnewswire
April 17, 2019
AB2 Bio Announces Readiness for Recruitment in Pivotal Phase 3 Trial of Tadekinig Alfa, a Novel Human Recombinant Interleukin-18 Binding Protein...